Loading company…
Syneron Bio develops macrocyclic peptide drugs for cancer, autoimmune, and rare diseases.
Founded in 2025 and based in Beijing, China, Syneron Bio uses its Synova™ platform to develop macrocyclic peptide drug candidates. In March 2026, it closed USD 150 million in Series B funding co-led by Decheng Capital and CDH Investments, with participation from Sinovation Ventures, 5Y Capital, GL Ventures, Lenovo Capital and Incubator Group, Abu Dhabi Investment Authority, True Light Capital, Qiming Venture Partners, BioTrack Capital, Lilly Asia Ventures, and Biotech Development Fund.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in